From September 2014-April 2015, six persons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agents rVSV-ZEBOV or TKM-100802 for post-exposure prophylaxis and were monitored in the U.S. All patients experienced self-limited symptoms after PEP; none developed Ebola virus disease.
Background
Post-exposure prophylaxis (PEP) after Ebola virus (EBOV) exposure can prevent infection or progression to severe Ebola virus disease (EVD) when administered promptly in non-human primates [1, 2] . Whether PEP prevents EVD after EBOV exposure in humans is unknown. Effective PEP is desirable to reduce progression to EVD after EBOV exposures, especially among healthcare personnel (HCP), who have a higher EVD incidence than non-HCP [3] .
A few individuals were evacuated from West Africa to the U.S. after potential EBOV exposures and received PEP through FDA-approved emergency Investigation New Drug applications (eIND).
Investigational PEP strategies include a recombinant vesicular stomatitis virus vaccine that expresses a
Zaire ebolavirus surface glycoprotein (rVSV-ZEBOV), a small interfering RNA known as TKM-100802, favipiravir (RNA polymerase inhibitor), and ZMapp (monoclonal antibody cocktail against EBOV glycoprotein).
Limited human data exist about PEP use for potential EBOV exposures and symptoms experienced after PEP administration. Previous reports described rVSV-ZEBOV administration to two physicians and a laboratory worker with percutaneous EBOV exposures [4] [5] [6] . One report of HCP medically evacuated to the U.K. after potential EBOV exposure described four individuals given PEP including favipiravir and monoclonal antibody cocktails ZMab, and MIL77 [7] . Of the seven patients described in these case reports who received investigational PEP, none developed EVD. We describe PEP use among six persons monitored in the U.S who experienced potential EBOV exposures during 2014-
2015.

Methods
This retrospective case series includes all persons who received PEP after a potential EBOV exposure in West Africa. Exposures included suspected percutaneous exposure to blood or body fluids of an EVD patient, direct contact with an EVD patient while wearing inappropriate or compromised PPE, or other exposure thought to be of sufficient risk to warrant medical evacuation and consideration of PEP from September 2014-April 2015. Decisions about medical evacuation, whether to initiate PEP, which investigational agent would be used for PEP, the duration of hospital monitoring, and clinical and laboratory monitoring of PEP recipients, were made by clinicians at the treating facilities with input from public health authorities. The rVSV-ZEBOV vaccine was made available under an eIND application to the Food and Drug Administration; the protocol specified a dose of 10 8 pfu. TKM-100802 was also made available under an eIND application. All patients were monitored initially in U.S. healthcare facilities.
EBOV nucleic acid testing of blood specimens was performed at USAMRIID using the EZ1 Real-time RT-PCR Assay or at the Centers for Disease Control and Prevention (CDC) using the CDC Ebola Virus NP and VP40 Real-time RT-PCR Assays. Clinicians who cared for PEP recipients were contacted to perform chart review using a standardized form to abstract patient characteristics, EBOV exposures, signs and symptoms after PEP administration, and laboratory results. Data were aggregated and summary results are presented. Data for one case were published previously [4] . This activity was determined to be non-research not requiring an Institutional Review Board determination at CDC.
Results
Six persons received PEP for a potential EBOV exposure assessed to be of sufficiently high risk from
September 2014-April 2015. These included three nurses and two physicians who were working in Ebola treatment units (ETUs) when the exposures occurred, and one non-clinician worker ( Table 1 ). All potential EBOV exposures were confirmed or suspected percutaneous exposures that occurred in Sierra Leone; five occurred in ETU patient care areas, and one occurred outside of a nearby ETU (Table 1) . Half (3) of injuries involved hollow-bore needles, and two involved broken medication ampules; one injury occurred with an unknown sharp object. One person noticed the injury upon doffing personal protective equipment (PPE); the others recognized the injury immediately. No sharps were known to be contaminated with EBOV; however, the sharp penetrated potentially contaminated PPE in four PEP recipients. One PEP recipient was not wearing any PPE at the time of injury. Percutaneous injuries occurred while administering medication (3), disposing of sharps (2) , and turning a patient with EVD in bed (1) . Upon recognizing the injury, all PEP recipients decontaminated the wound site within 15 minutes with a chlorine solution. All were medically evacuated to the U.S. within 2-3 days of injury.
Five patients received rVSV-ZEBOV at a dose of 10 8 pfu in a 1 mL solution; one received multiple TKM-100802 doses at 0.3-0.5 mg/kg daily. Time from EBOV exposure to PEP initiation was 1-3 days. Two began PEP while in West Africa; four began PEP on the medical evacuation flight. HIV post-exposure prophylaxis was given to four individuals; the remaining two declined this intervention.
All PEP recipients were isolated in U.S. healthcare facilities with at least standard, contact and droplet precautions initially; length of stay ranged from 3-19 days. All reported symptoms that began ≤1 day after PEP initiation ( Table 2 ). Of five who received rVSV-ZEBOV, the most commonly reported side effects were fever (4), headache (4), and nausea (4) . Fever among rVSV-ZEBOV recipients began 12-24 hours after rVSV-ZEBOV administration. Diarrhea was reported among two rVSV-ZEBOV recipients; diarrhea started 2 days after rVSV-ZEBOV administration for one, and the other had diarrhea that started one day prior to rVSV-ZEBOV administration. One rVSV-ZEBOV recipient vomited 4 days after PEP initiation. One rVSV-ZEBOV recipient developed a rash that appeared one day after PEP initiation and lasted for 18 days. Another rVSV-ZEBOV recipient reported joint pain starting on the day of PEP initiation and resolving by the next day. Three rVSV-ZEBOV recipients reported pain at the injection site.
The TKM-100802 recipient developed a fever 48 hours after the first dose and developed redness, swelling, pain, and thrombophlebitis at multiple injection sites. All patients had resolved symptoms upon hospital discharge and were monitored through 21 days after their potential EBOV exposure.
No patients had laboratory evidence of EBOV infection. The EBOV glycoprotein, which is expressed by rVSV-ZEBOV, was detected in blood by RT-PCR in four of five rVSV-ZEBOV recipients.
Three rVSV-ZEBOV recipient had detectable IgM and IgG antibodies to EBOV glycoprotein after vaccination [4] . EBOV glycoprotein was not detected in blood by RT-PCR for the TKM-100802 recipient. Among rVSV-ZEBOV recipients, EBOV nucleoprotein was not detected in blood collected ≥3 days after exposure by RT-PCR. Three rVSV-ZEBOV recipients had RT-PCR for VSV nucleoprotein performed on blood; all had VSV detected.
Discussion
We describe six individuals who received PEP after potential EBOV exposures; none had RT-PCR evidence of EBOV infection and none developed EVD. All patients reported symptoms after PEP administration which may have been attributable to PEP or to other factors, such as anxiety, stress, fatigue related to medical evacuation, or other medications including PEP for HIV.
Safety studies of rVSV-ZEBOV among healthy volunteers have shown that rVSV-ZEBOV is generally well tolerated; early reactogenicity symptoms are common, and rare occurrences of arthritis and vesicular dermatitis have been reported [8] [9] [10] . While one of the five rVSV-ZEBOV recipients reported joint pain, none reported arthritis; one person reported a rash. All PEP recipients' symptoms resolved by the time of hospital discharge. An ongoing ring vaccination trial, designed to examine use of rVSV-ZEBOV at a lower dose of 2 x 10 7 pfu/mL for rapid pre-exposure prophylaxis rather than for PEP [11] , may provide additional data on safety, efficacy in prevention of EVD, and duration of protection [12] .
Additional vaccine trials that aim to immunize healthcare and other frontline workers prior to an EBOV exposure event are ongoing [13] .
Of the few reports of TKM-100802 for treatment of EVD, fever and rigors were described in one patient, the drug was discontinued in another patient due to multi-organ system failure, and a third patient experienced hypotension after the initial infusion [14, 15] . The patient who received TKM-100802 for EBOV PEP experienced fever and injection site reactions, and therapy was stopped after dose 5 of 7 due to these side effects.
This report is subject to limitations. The small number of PEP recipients makes it difficult to generalize any of the clinical findings. PEP was uncontrolled; therefore, we cannot determine whether rVSV-ZEBOV or TKM-100802 were effective in preventing EVD. While the exposures described among PEP recipients were assumed to be high risk for the purpose of public health monitoring, it was not determined whether EBOV exposure actually occurred since no testing was performed on the sharps or PPE to document presence of EBOV.
None of the PEP recipients reported here or previously [4] [5] [6] 
